The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer
Abstract
Purpose: Men with localized prostate cancer often are treated with external radiotherapy (RT) over 8 to 9 weeks. Hypofractionated RT is given over a shorter time with larger doses per treatment than standard RT. We hypothesized that hypofractionation versus conventional fractionation is similar in efficacy without increased toxicity. Patients and Methods: We conducted a multicenter randomized noninferiority trial in intermediate-risk prostate cancer (T1 to 2a, Gleason score ≤ 6, and prostate-specific antigen [PSA] 10.1 to 20 ng/mL; T2b to 2c, Gleason ≤ 6, and PSA ≤ 20 ng/mL; or T1 to 2, Gleason = 7, and PSA ≤ 20 ng/mL). Patients were allocated to conventional RT of 78 Gy in 39 fractions over 8 weeks or to hypofractionated RT of 60 Gy in 20 fractions over 4 weeks. Androgen deprivation was not permitted with therapy. The primary outcome was biochemical-clinical failure (BCF) defined by any of the following: PSA failure (nadir + 2), hormonal intervention, clinical local or distant failure, or death as a result of prostate cancer. The noninferiority margin was 7.5% (hazard ratio, < 1.32). Results: Median follow-up was 6.0 years. One hundred nine of 608 patients in the hypofractionated arm versus 117 of 598 in the standard arm experienced BCF. Most of the events were PSA failures. The 5-year BCF disease-free survival was 85% in both arms (hazard ratio [short v standard], 0.96; 90% CI, 0.77 to 1.2). Ten deaths as a result of prostate cancer occurred in the short arm and 12 in the standard arm. No significant differences were detected between arms for grade ≥ 3 late genitourinary and GI toxicity. Conclusion: The hypofractionated RT regimen used in this trial was not inferior to conventional RT and was not associated with increased late toxicity. Hypofractionated RT is more convenient for patients and should be considered for intermediate-risk prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
WARE, J. E., KOSINSKI, M., & KELLER, S. D. (1996) · Medical Care · doi:10.1097/00005650-199603000-00003 · Cited by 17,392
Roach, M., Hanks, G., Thames, H., Schellhammer, P., Shipley, W. U., Sokol, G. H., & Sandler, H. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2006.04.029 · Cited by 2,749
Partin, A. W. (1997) · JAMA · doi:10.1001/jama.277.18.1445 · Cited by 1,794
Wei, J. T., Dunn, R. L., Litwin, M. S., Sandler, H. M., & Sanda, M. G. (2000) · Urology · doi:10.1016/s0090-4295(00)00858-x · Cited by 1,520
Dearnaley, D., Syndikus, I., Mossop, H., Khoo, V., Birtle, A., Bloomfield, D., Graham, J., Kirkbride, P., Logue, J., Malik, Z., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30102-4 · Cited by 1,339
Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial
Pollack, A., Zagars, G. K., Starkschall, G., Antolak, J. A., Lee, J. J., Huang, E., von Eschenbach, A. C., Kuban, D. A., & Rosen, I. (2002) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(02)02829-8 · Cited by 1,333
Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer
Kuban, D. A., Tucker, S. L., Dong, L., Starkschall, G., Huang, E. H., Cheung, M. R., Lee, A. K., & Pollack, A. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.06.054 · Cited by 1,232
Consensus statement: Guidelines for PSA following radiation therapy1
AMERICANSOCIETYFORTHERAPEUTICR (1997) · International Journal of Radiation OncologyBiologyPhysics · doi:10.1016/s0360-3016(97)00002-3 · Cited by 1,151
Dearnaley, D. P., Sydes, M. R., Graham, J. D., Aird, E. G., Bottomley, D., Cowan, R. A., Huddart, R. A., Jose, C. C., Matthews, J. H., Millar, J., et al. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70143-2 · Cited by 905
Dearnaley, D. P., Khoo, V. S., Norman, A. R., Meyer, L., Nahum, A., Tait, D., Yarnold, J., & Horwich, A. (1999) · The Lancet · doi:10.1016/s0140-6736(98)05180-0 · Cited by 739
Zietman, A. L., Bae, K., Slater, J. D., Shipley, W. U., Efstathiou, J. A., Coen, J. J., Bush, D. A., Lunt, M., Spiegel, D. Y., Skowronski, R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.8475 · Cited by 735
ZELEFSKY, M. J., FUKS, Z., HUNT, M., LEE, H. J., LOMBARDI, D., LING, C. C., REUTER, V. E., VENKATRAMAN, E. S., & LEIBEL, S. A. (2001) · Journal of Urology · doi:10.1016/s0022-5347(05)65855-7 · Cited by 697
Brenner, D. J., Martinez, A. A., Edmundson, G. K., Mitchell, C., Thames, H. D., & Armour, E. P. (2002) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(01)02664-5 · Cited by 650
Is α/β for prostate tumors really low?
Fowler, J., Chappell, R., & Ritter, M. (2001) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(01)01607-8 · Cited by 628
Lee, W. R., Dignam, J. J., Amin, M. B., Bruner, D. W., Low, D., Swanson, G. P., Shah, A. B., D’Souza, D. P., Michalski, J. M., Dayes, I. S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.0448 · Cited by 625
Self-citationIncrocci, L., Wortel, R. C., Alemayehu, W. G., Aluwini, S., Schimmel, E. C., Krol, A. D. G., van der Toorn, P.-P., de Jager, H., Heemsbergen, W. D., Heijmen, B. J. M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30070-5 · Cited by 525
Miralbell, R., Roberts, S. A., Zubizarreta, E., & Hendry, J. H. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.10.075 · Cited by 523
Randomized Trial of Hypofractionated External-Beam Radiotherapy for Prostate Cancer
Pollack, A., Walker, G., Horwitz, E. M., Price, R., Feigenberg, S., Konski, A. A., Stoyanova, R., Movsas, B., Greenberg, R. E., Uzzo, R. G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.1972 · Cited by 464
Dearnaley, D. P., Jovic, G., Syndikus, I., Khoo, V., Cowan, R. A., Graham, J. D., Aird, E. G., Bottomley, D., Huddart, R. A., Jose, C. C., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70040-3 · Cited by 463
Randomized Trial Comparing Two Fractionation Schedules for Patients With Localized Prostate Cancer
Lukka, H., Hayter, C., Julian, J. A., Warde, P., Morris, W. J., Gospodarowicz, M., Levine, M., Sathya, J., Choo, R., Prichard, H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.153 · Cited by 349
Self-citationAluwini, S., Pos, F., Schimmel, E., Krol, S., van der Toorn, P. P., de Jager, H., Alemayehu, W. G., Heemsbergen, W., Heijmen, B., & Incrocci, L. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00567-7 · Cited by 309
Dose selection for prostate cancer patients based on dose comparison and dose response studies
Hanks, G. E., Hanlon, A. L., Pinover, W. H., Horwitz, E. M., Price, R., & Schultheiss, T. E. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(99)00498-8 · Cited by 156
Syndikus, I., Morgan, R. C., Sydes, M. R., Graham, J. D., & Dearnaley, D. P. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.05.052 · Cited by 92
Cited by
Mottet, N., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Cumberbatch, M. G., De Santis, M., Fanti, S., Fossati, N., Gandaglia, G., Gillessen, S., et al. (2021) · European Urology · doi:10.1016/j.eururo.2020.09.042 · Cited by 2,802
Widmark, A., Gunnlaugsson, A., Beckman, L., Thellenberg-Karlsson, C., Hoyer, M., Lagerlund, M., Kindblom, J., Ginman, C., Johansson, B., Björnlinger, K., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31131-6 · Cited by 876
Tree, A. C., Ostler, P., van der Voet, H., Chu, W., Loblaw, A., Ford, D., Tolan, S., Jain, S., Martin, A., Staffurth, J., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00517-4 · Cited by 313
Self-citation
Metadata
- Authors
- Catton, C. N., Lukka, H., Gu, C.-S., Martin, J. M., Supiot, S., Chung, P. W. M., Bauman, G. S., Bahary, J.-P., Ahmed, S., Cheung, P., Tai, K. H., Wu, J. S., Parliament, M. B., Tsakiridis, T., Corbett, T. B., Tang, C., Dayes, I. S., Warde, P., Craig, T. K., Julian, J. A., & Levine, M. N.
- Venue
- Journal of Clinical Oncology
- Published
- 2017-06-10
- Volume
- 35
- Issue
- 17
- Pages
- 1884-1890
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2603384438
- Cited by
- 713
- References
- 24
- FWCI
- 57.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.